FIP1L1-PDGFRА-positive myeloproliferative disease with eosinophilia: A rare case with multiple organ dysfunction and a response to tyrosine kinase inhibitor therapy


Cite item

Full Text

Abstract

The described case of FIP1L1-PDGFRА-positive myeloproliferative disease is characterized by an atypical aggressive course to develop severe specific complications as injuries to the brain, heart, lung, and intestine. Pathogenetic therapy with imatinib could stabilize a patient’s state, but failed to produce a complete hematological response. Switching from imatinib to dasatinib could produce sustained clinical, hematological, and molecular remissions.

References

  1. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975;54:1-27.
  2. Weller P, Bubley G. The idiopathic hypereosinophilic syndrome. Blood. 1994;83:2759-2779.
  3. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14-22.
  4. Baxter EJ, Hochhaus A, Bolufer P, Reiter A, Fernandez JM, Senent L, Cervera J, Moscardo F, Sanz MA, Cross NCP. The t(4;22)(q12;q11) in atypical chronic myeloid leukemia fuses BCR to PDGFRA. Human Mol Genet. 2002;11(12):1391-1397.
  5. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
  6. Griffin JH, Leung J, Bruner RJ, Caligiur MA, Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. PNAS. 2003;100(13):7830-7835.
  7. Pardanani А, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li C-Y, Cross NCP, Cools J, Gilliland DG, Dewald GW, Tefferi A. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 2003;102(9):3093-3096.
  8. Klion AD, Robin J, Akin C, Noel P, Brown M, Law M, Metcalfe DD, Dunbar C, Nutmanet TB. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004;103(2):473-478.
  9. Vandenberghe P, Wlodarska I, Michaux L, Zachée P, Boogaerts M, Vanstraelen D, Herregods M-C, Van Hoof A, Selleslag D, Roufosse F, Maerevoet M, Verhoef G, Cools J, Gilliland DG, Hagemeijer A, Marynen P. Clinical and molecular features of FIP1L1-PDGFRA (+) chronic eosinophilic leukemias. Leukemia. 2004;18(4):734-742.
  10. Pardanani А, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL, Ho C-L, Li C-Y, Dewald GW, Tefferi A. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004;104(10):3038-3045.
  11. Frickhofen N, Marker-Hermann E, Reiter A, Walz C, Jung B, Bauer H, Hochhaus A. Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib. Ann Hematol. 2004;83:477-480.
  12. Rose C, Dupire S, Roche-Lestienne C, Grardel N, Bourgeois E, Cambier N, Preudhomme C. Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft. Leukemia. 2004;18:354-355.
  13. Stover EH, Chen J, Lee BH, Cools J, McDowell E, Adelsperger J, Cullen D, Coburn A, Moore SA, Fabbro D, Manley PW, Griffin JD, Gilliland GD. The small molecule tirosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood. 2005;106(9):3206-3213.
  14. La Starza R, Specchia G, Cuneo A, Beacci D, Nozzoli C, Luciano L, Aventin A, Sambani C, Testoni N, Foppoli M, Invernizzi R, Marynen P, Martelli MF, Mecucci C. The hypereosinophilic syndrome: fluorescense in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases. Haematologica. 2005;90(5):596-601.
  15. Немченко И.С., Хорошко Н.Д., Туркина А.Г., Соколова М.А., Кохно А.В., Семенова Е.А., Захарова А.В. FIP1L1-PDGFRα-позитивное миелопролиферативное заболевание с гиперэозинофилией: клиническая характеристика и возможности патогенетической терапии. Терапевтический архив 2005;7:90-92.
  16. Robyn J, Lemery S, McCoy JP, Kubofcik J, Kim Y-J, Pack S, Nutman TB, Dunbar D, Klion AD. Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome. Br J Haematol. 2006;132(3):286-292.
  17. Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G, Erben P, Popp H, Walz C, Hochhaus A, Roche-Lestienne C, Preudhomme C, Solomon E, Apperley J, Rondoni M, Ottaviani E, Martinelli G, Brito-Babapulle F, Saglio G, Hehlmann R, Cross NCP, Reiter A, Grimwade D. Low-dose imatanib mesylate leads to rapid induction of major molecular responses and achivement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood. 2007;109(11):4635-4640.
  18. Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, Tiribelli M, Buccisano F, Testoni N, Gottardi E, de Vivo A, Giugliano E, Iacobucci I, Paolini S, Soverini S, Rosti G, Rancati F, Astolfi C, Pane F, Saglio G, Martinelli G. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica. 2007;92(9):1173-1179.
  19. Klion AD, Robin J, Maric I, Fu W, Schmid L, Lemery S, Noel P, Law MA, Hartsell M, Talar-Williams C, Fay MP, Dunbar CE, Nutman TB. Relapse following discontinuating of imatinib mesylate therapy for FIP1L1-PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood. 2007;110(10):3552-3556.
  20. Mitra S, Thornton P. Chronic eosinophilic leukemia (associated with FIP1L1-PDGFRA) — dramatic response to imatinib mesylate. Haematologica. 2007, Abstract 1480.
  21. Gotlib J, Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other moleculary defined eosinophilias. Leukemia. 2008;22(11):1999-2010.
  22. Simon D, Salemi S, Yousefi S, Simon HU. Primary resistance to imatanib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia. J Allergy Clin Immunol. 2008;121(4):1054-1056.
  23. Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C, Fabarius A, Schnittger S, Grimwade D, Cross NCP, Hehlmann R, Hochhaus A, Reiter A. Safety and efficacy of imatanib mesylate in chronic eosinophilic leukemia and hypereosinophilic syndrome: a phase II study. Br J Haematol. 2008;143(5):707-715.
  24. Williams C, Kalra S, Nath U, Bown N, Wilson V, Wilkins BS, Neylon AJ. FIP1L1-PDGFRA positive chronic eosinophilic leukemia and associated central nervous system involvement. J Clin Pathol. 2008;61:677-680.
  25. Intermesoli T, Delaini F, Salmoiraghi S, Acerboni S, Guerini V, Vannucci A, Mappa S, Rossi G, Rossi V, Di Bona E, Carobbio A, Barbui T, Rambaldi A, Bassan R. A time and dose to response study of imatinib therapy for chronic hypereosinophilic syndromes. Haematologica. 2008,Abstract 0152.
  26. Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, Leiferman KM, Nutman TB, Pfab F, Ring J, Rothenberg ME, Roufosse F, Sajous M, Sheikh J, Simon D, Simon H-U, Stein ML, Wardlaw A, Weller PF, Klion AD. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009;124(6):1319-1325.
  27. Lierman E, Michaux L, Beullens E, Pierre P, Marynen P, Cools J, Vandenberghe P. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia. 2009;23(5):845-851.
  28. Score J, Walz C, Jovanovic JV, Jones AV, Waghorn K, Hidalgo-Kurtis C, Lin F, Grimwade D, Grand F, Reiter A, Cross NC. Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions. Leukemia. 2009;23(2):332-339.
  29. Lim K-H, Tefferi A, Li CY, Pardanani AD. Hypereosinophilia in 357 Consecutive Patients: Disease Spectrum and Clinical and Laboratory Correlates. ASH Annual Meeting Abstracts 2009, Abstract 3903.
  30. Metzgeroth G, Erben P, Walz C, Gosenca D, Mix J, Haferlach C, Schnittger S, Cross NCP, Hochhaus A, Reiter A. Primary and secondary resistance to imatinib is very rare in chronic and blast phase of myeloproliferative neoplasms with rearrangements of PDGFRA and PDGFRB. Haematologica. 2009, Abstract 0649.
  31. Verstovsek S. Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemia and myeloid disorders. Leuk Res. 2009;33:617-623.
  32. Ikezoe T, Togitani K, Tasaka T, Nishioka C, Yokoyama A. Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib. LeukRes. 2010;34(8):e200-e201. doi: 10.1016/j.leukres.2010.02.024.
  33. Helbig G, Moskwa A, Hus M, Piszcz J, Swiderska A, Urbanowicz A, Całbecka M, Seferyńska I, Raźny M, Rodzaj M, Żuk E, Kyrcz-Krzemień S. Durable remission after treatment with low doses of imatinib for FIP1L1/PDGFRα-positive chronic eosinophilic leukemia. Cancer Chemother Pharmacol. 2011;67(4):967-696. doi: 10.1007/s00280-011-1582-3.
  34. Simon HU, Klion A. Therapeutic approaches to patients with hypereosinophilic syndromes. Semin Hematol. 2012;49(2): 160-170. doi: 10.1053/j.seminhematol.2012.01.002.
  35. Metzgeroth G, Erben P, Martin H, Mousset S, Teichmann M, Walz C, Klippstein T, Hochhaus A, Cross NCP, Hofmann W-K, Reiter A. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia. 2012;26(1): 162-164. doi: 10.1038/leu.2011.181.
  36. Немченко И.С., Туркина А.Г., Соколова М.А., Домрачева Е.В., Мисюрин А.В., Семенова Е.А., Кохно А.В., Марголин О.В., Хорошко Н.Д. Результаты лечения миелопролиферативных заболеваний, протекающих с эозинофилией, и идиопатического гиперэозинофильного синдрома. Гематология и трансфузиология. 2012;57(3):16.
  37. Хорошко Н.Д., Мокеева Р.А., Абакумов Е.М., Немченко И.С., Семенова Е.А., Захарова А.В., Кобзев Ю.Н., Сурин В.Л., Духовенская Е.А., Федорова С.Ю. Диффузное поражение головного мозга при гиперэозинофильном варианте Ph’-отрицательного, BCR-ABL-положительного варианта хронического миелолейкоза. Гематология и трансфузиология 2000;45(2):30-35.
  38. Awano N, Ryu T, Yoshimura N, Takazoe M, Kitamura S, Tanaka M. Successful Treatment of Ulcerated Colitis Associated with Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia. Intern Med. 2011;50:1741-1745.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies